BUSINESS

Takeda Poised to Weather LOEs in Next 2 Years with 10 Growth Drivers: CEO

By Yoshinori Sagehashi May 12, 2022
Takeda Pharmaceutical CEO Christophe Weber on May 11 expressed his confidence about the company’s ability to overcome the impact of major patent expirations in the next two years with strong performances anticipated for 10 growth drivers including Entyvio (vedolizumab). Velcade…

To read the full story

Related Article

BUSINESS

By Reiji Anasako

The Japan presidents of foreign pharma companies are no longer hiding their concerns about the stagnation of drug development in the Japanese market. In their business briefings for 2021, many of them made explicit criticism against what they see as…

By Philip Carrigan

The missing ingredient for managers is not their skill, ability, or education. Academic achievements and business success will get runs on the board, to a certain level. However, that is just half of the story.Leaders come in all shapes and…

By Reiji Anasako

The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…

Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…

Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…

A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…